Genetic
Menu
About us
READ-GENE is based on an increasingly widespread global assumption that the development of cancer has a genetic basis, and by selecting the correspondent genes, effective prevention of cancer is possible. READ-GENE SA operates in the field of so-called "personalized medicine," which means that each patient is treated individually based on genetic tests. This is an innovative approach to patient care, making prevention and treatment more efficient and effective than general methods used for the entire population.
The company's primary business segments are chemoprevention, clinical research, and genetic testing. All of these segments are complementary to each other.
Chemoprevention
Chemoprevention involves the use of natural or synthetic substances to inhibit, reverse, or delay the process of developing cancer. This is the segment of the company's activities that receives the most attention. To implement the most natural form of prevention, the company distributes supplements and food products with controlled levels of micronutrients and vitamins. Consuming appropriate food products is an option aimed at general health benefits. As indicated by the results of recent scientific analyses, it also significantly reduces the risk of developing cancer.
Clinical trials
Clinical trials involves evaluating whether a potential drug, product, or medical technology is effective, safe, and fulfills its primary objectives. READ-GENE offers its services in this dimension to corporate clients, primarily from the medical, pharmaceutical, chemical, and biotechnological industries. The company's innovation in conducting clinical research lies in selecting patients with a defined genetic profile for these studies. Thanks to having the world's largest registry of data and a bank of genetic samples, including over 2,000,000 patient records and over 700,000 DNA samples, of which more than 10,000 are diagnosed and registered carriers of BRCA1 mutations and more than 21,000 carriers of CHEK2, NOD2, NBS1 CDKN2A, CYP1B1, NBN, p53, FGFR, and other gene mutations, READ-GENE recruited the largest number of patients in the world for two clinical studies commissioned by pharmaceutical companies, for which it received commendation letters. Genetic tests and genetic-oncological consultations are available to all patients. The company operates an online platform in both Polish and English. The company's intellectual value includes 8 granted foreign patents and 18 granted Polish patents. The company has also submitted numerous other patent applications, some of which are currently undergoing the patenting process.
Genetic tests and genetic-oncological consultations are available to all patients. The company operates an online platform in both Polish and English.
The company's intellectual property includes 8 granted foreign patents and 18 Polish. The company has also filed numerous other applications, with patent proceedings underway.
Genetic tests
Read-Gene has an exclusive license agreement with the Pomeranian Medical University for the use of technology based on intellectual property, including:
- Genetic tests available for the most common types of cancer - including breast, ovarian, prostate, stomach, and colorectal cancers.
- Promising preventive methods for breast cancer treatment.
- Databases and DNA sample repositories, as well as the methodology for comparing and utilizing these data.
- Clinical trials on patients with tumors identified with a genetic profile associated with an increased risk of cancer, such as studying the effects of drugs on patients with BRCA1 mutations.
Read-Gene also provides advisory services for genetic counseling and support for oncological genetic counseling centers. Read-Gene's approach to genetic testing significantly increases the likelihood of cancer prevention, early detection, and treatment, thus significantly reducing the costs of oncological care.
About us
READ-GENE is based on an increasingly widespread global assumption that the development of cancer has a genetic basis, and by selecting the correspondent genes, effective prevention of cancer is possible. READ-GENE SA operates in the field of so-called "personalized medicine," which means that each patient is treated individually based on genetic tests. This is an innovative approach to patient care, making prevention and treatment more efficient and effective than general methods used for the entire population.
The company's primary business segments are chemoprevention, clinical research, and genetic testing. All of these segments are complementary to each other.
Chemoprevention
Chemoprevention involves the use of natural or synthetic substances to inhibit, reverse, or delay the process of developing cancer. This is the segment of the company's activities that receives the most attention. To implement the most natural form of prevention, the company distributes supplements and food products with controlled levels of micronutrients and vitamins. Consuming appropriate food products is an option aimed at general health benefits. As indicated by the results of recent scientific analyses, it also significantly reduces the risk of developing cancer.
Clinical trials
Clinical trials involves evaluating whether a potential drug, product, or medical technology is effective, safe, and fulfills its primary objectives. READ-GENE offers its services in this dimension to corporate clients, primarily from the medical, pharmaceutical, chemical, and biotechnological industries. The company's innovation in conducting clinical research lies in selecting patients with a defined genetic profile for these studies. Thanks to having the world's largest registry of data and a bank of genetic samples, including over 2,000,000 patient records and over 700,000 DNA samples, of which more than 10,000 are diagnosed and registered carriers of BRCA1 mutations and more than 21,000 carriers of CHEK2, NOD2, NBS1 CDKN2A, CYP1B1, NBN, p53, FGFR, and other gene mutations, READ-GENE recruited the largest number of patients in the world for two clinical studies commissioned by pharmaceutical companies, for which it received commendation letters. Genetic tests and genetic-oncological consultations are available to all patients. The company operates an online platform in both Polish and English. The company's intellectual value includes 8 granted foreign patents and 18 granted Polish patents. The company has also submitted numerous other patent applications, some of which are currently undergoing the patenting process.
Genetic tests and genetic-oncological consultations are available to all patients. The company operates an online platform in both Polish and English.
The company's intellectual property includes 8 granted foreign patents and 18 Polish. The company has also filed numerous other applications, with patent proceedings underway.
Genetic tests
Read-Gene has an exclusive license agreement with the Pomeranian Medical University for the use of technology based on intellectual property, including:
- Genetic tests available for the most common types of cancer - including breast, ovarian, prostate, stomach, and colorectal cancers.
- Promising preventive methods for breast cancer treatment.
- Databases and DNA sample repositories, as well as the methodology for comparing and utilizing these data.
- Clinical trials on patients with tumors identified with a genetic profile associated with an increased risk of cancer, such as studying the effects of drugs on patients with BRCA1 mutations.
Read-Gene also provides advisory services for genetic counseling and support for oncological genetic counseling centers. Read-Gene's approach to genetic testing significantly increases the likelihood of cancer prevention, early detection, and treatment, thus significantly reducing the costs of oncological care.
About us
READ-GENE is based on an increasingly widespread global assumption that the development of cancer has a genetic basis, and by selecting the correspondent genes, effective prevention of cancer is possible. READ-GENE SA operates in the field of so-called "personalized medicine," which means that each patient is treated individually based on genetic tests. This is an innovative approach to patient care, making prevention and treatment more efficient and effective than general methods used for the entire population.
The company's primary business segments are chemoprevention, clinical research, and genetic testing. All of these segments are complementary to each other.
Chemoprevention
Chemoprevention involves the use of natural or synthetic substances to inhibit, reverse, or delay the process of developing cancer. This is the segment of the company's activities that receives the most attention. To implement the most natural form of prevention, the company distributes supplements and food products with controlled levels of micronutrients and vitamins. Consuming appropriate food products is an option aimed at general health benefits. As indicated by the results of recent scientific analyses, it also significantly reduces the risk of developing cancer.
Clinical trials
Clinical trials involves evaluating whether a potential drug, product, or medical technology is effective, safe, and fulfills its primary objectives. READ-GENE offers its services in this dimension to corporate clients, primarily from the medical, pharmaceutical, chemical, and biotechnological industries. The company's innovation in conducting clinical research lies in selecting patients with a defined genetic profile for these studies. Thanks to having the world's largest registry of data and a bank of genetic samples, including over 2,000,000 patient records and over 700,000 DNA samples, of which more than 10,000 are diagnosed and registered carriers of BRCA1 mutations and more than 21,000 carriers of CHEK2, NOD2, NBS1 CDKN2A, CYP1B1, NBN, p53, FGFR, and other gene mutations, READ-GENE recruited the largest number of patients in the world for two clinical studies commissioned by pharmaceutical companies, for which it received commendation letters. Genetic tests and genetic-oncological consultations are available to all patients. The company operates an online platform in both Polish and English. The company's intellectual value includes 8 granted foreign patents and 18 granted Polish patents. The company has also submitted numerous other patent applications, some of which are currently undergoing the patenting process.
Genetic tests and genetic-oncological consultations are available to all patients. The company operates an online platform in both Polish and English.
The company's intellectual property includes 8 granted foreign patents and 18 Polish. The company has also filed numerous other applications, with patent proceedings underway.
Genetic tests
Read-Gene has an exclusive license agreement with the Pomeranian Medical University for the use of technology based on intellectual property, including:
- Genetic tests available for the most common types of cancer - including breast, ovarian, prostate, stomach, and colorectal cancers.
- Promising preventive methods for breast cancer treatment.
- Databases and DNA sample repositories, as well as the methodology for comparing and utilizing these data.
- Clinical trials on patients with tumors identified with a genetic profile associated with an increased risk of cancer, such as studying the effects of drugs on patients with BRCA1 mutations.
Read-Gene also provides advisory services for genetic counseling and support for oncological genetic counseling centers. Read-Gene's approach to genetic testing significantly increases the likelihood of cancer prevention, early detection, and treatment, thus significantly reducing the costs of oncological care.